Literature DB >> 23317678

Impact of estimated glomerular filtration rate on vascular disease extent and adverse cardiovascular events in patients without chronic kidney disease.

Yaron Arbel1, Amir Halkin, Ariel Finkelstein, Miri Revivo, Shlomo Berliner, Itzhak Herz, Gad Keren, Shmuel Banai.   

Abstract

BACKGROUND: Estimated glomerular filtration rate (eGFR) predicts major adverse cardiovascular events (MACE) in patients with chronic kidney disease (CKD), though the effect of eGFR on MACE and vascular disease extent among individuals with normal or mildly impaired renal function requires definition. Our aim was to examine the prognostic implications of eGFR and its effect on atherosclerosis burden in individuals without CKD undergoing vascular imaging studies.
METHODS: The study enrolled 2746 consecutive patients undergoing clinically-driven coronary angiography who had an eGFR > 60 mL/min/1.73 m(2) and no history of CKD. Same-day carotid duplex results were available for 317 patients. Patients were followed for up to 3 years for the occurrence of all-cause mortality, myocardial infarction, and stroke.
RESULTS: After adjustment for potential clinical and biochemical confounders, eGFR was found to be independently associated with coronary artery disease extent in the entire study population and among patients with normal renal function (n = 1170; eGFR > 90 mL/min/1.73 m(2)): odds ratio (OR) = 1.16 (95% confidence interval [CI], 1.09-1.24) and OR = 1.25 (95% CI, 1.11-1.4) per 10 mL/min decrements in eGFR, respectively. Similarly, eGFR was independently associated with carotid artery stenosis in the entire cohort (OR, 1.86 [95% CI, 1.12-3.1]). By Cox regression analysis, eGFR was an independent predictor of the composite MACE end point (hazard ratio, 1.16 [95% CI, 1.04-1.28]), and all-cause mortality (hazard ratio, 1.38 [95% CI, 1.19-1.60]).
CONCLUSIONS: eGFR is an independent predictor of atherosclerotic vascular disease extent and MACE rates in patients with normal or mildly impaired renal function.
Copyright © 2013 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23317678     DOI: 10.1016/j.cjca.2012.10.014

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  12 in total

1.  Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study.

Authors:  Lene Ryom; Jens D Lundgren; Mike Ross; Ole Kirk; Matthew Law; Philippe Morlat; Eric Fontas; Colette Smit; Christoph A Fux; Camilla I Hatleberg; Stéphane de Wit; Caroline A Sabin; Amanda Mocroft
Journal:  J Infect Dis       Date:  2016-08-02       Impact factor: 5.226

2.  Prognostic Implications of Acute Renal Impairment among ST Elevation Myocardial Infarction Patients with Preserved Left Ventricular Function.

Authors:  Yacov Shacham; Amir Gal-Oz; Jeremy Ben-Shoshan; Gad Keren; Yaron Arbel
Journal:  Cardiorenal Med       Date:  2016-02-03       Impact factor: 2.041

3.  Red blood cell distribution width and 3-year outcome in patients undergoing cardiac catheterization.

Authors:  Yaron Arbel; Edo Y Birati; Ariel Finkelstein; Amir Halkin; Shlomo Berliner; Ben-Zion Katz; Miri Revivo; Hila Saranga; Itzhak Herz; Gad Keren; Shmuel Banai
Journal:  J Thromb Thrombolysis       Date:  2014-05       Impact factor: 2.300

4.  Performance of the Cockcroft-Gault, MDRD and CKD-EPI Formulae in Non-Valvular Atrial Fibrillation: Which one Should be Used for Risk Stratification?

Authors:  Sérgio Barra; Rui Providência; Catarina Faustino; Luís Paiva; Andreia Fernandes; António Leitão Marques
Journal:  J Atr Fibrillation       Date:  2013-10-31

5.  Decline in serum cholinesterase activities predicts 2-year major adverse cardiac events.

Authors:  Yaron Arbel; Shani Shenhar-Tsarfaty; Nir Waiskopf; Ariel Finkelstein; Amir Halkin; Miri Revivo; Shlomo Berliner; Itzhak Herz; Itzhak Shapira; Gad Keren; Hermona Soreq; Shmuel Banai
Journal:  Mol Med       Date:  2014-02-12       Impact factor: 6.354

Review 6.  Acute kidney injury among ST elevation myocardial infarction patients treated by primary percutaneous coronary intervention: a multifactorial entity.

Authors:  Yacov Shacham; Arie Steinvil; Yaron Arbel
Journal:  J Nephrol       Date:  2016-02-10       Impact factor: 3.902

7.  Long term prognosis of acute coronary syndrome with chronic renal dysfunction treated in different therapy units at department of cardiology: a retrospective cohort study.

Authors:  Cong Fu; Zulong Sheng; Yuyu Yao; Xin Wang; Chaojun Yu; Genshan Ma
Journal:  Int J Clin Exp Med       Date:  2015-10-15

8.  Predictors of Subclinical Atheromatosis Progression over 2 Years in Patients with Different Stages of CKD.

Authors:  Marta Gracia; Àngels Betriu; Montserrat Martínez-Alonso; David Arroyo; María Abajo; Elvira Fernández; José M Valdivielso
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-14       Impact factor: 8.237

9.  Admission glucose, fasting glucose, HbA1c levels and the SYNTAX score in non-diabetic patients undergoing coronary angiography.

Authors:  Yaron Arbel; Margalit Zlotnik; Amir Halkin; Ofer Havakuk; Shlomo Berliner; Itzhak Herz; Itay Rabinovich; Gad Keren; Shmuel Bazan; Ariel Finkelstein; Shmuel Banai
Journal:  Clin Res Cardiol       Date:  2013-11-24       Impact factor: 5.460

10.  Elective open suprarenal aneurysm repair in England from 2000 to 2010 an observational study of hospital episode statistics.

Authors:  Alan Karthikesalingam; Peter J E Holt; Benjamin O Patterson; Alberto Vidal-Diez; Giuseppe Sollazzo; Jan D Poloniecki; Robert J Hinchliffe; Matthew M Thompson
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.